COVID-19: Lessons learned at the 5-year mark
As New York City marks five years since the first confirmed case of COVID-19, the NYC Preparedness & Recovery Institute (PRI) is reflecting on the city’s response to… read more.
As New York City marks five years since the first confirmed case of COVID-19, the NYC Preparedness & Recovery Institute (PRI) is reflecting on the city’s response to… read more.
AbbVie announced the final analysis of the confirmatory Phase III MIRASOL trial evaluating the efficacy and safety of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive… read more.
Patients at high risk of heart attack and stroke should be treated with a combination of a statin and ezetimibe, and as soon as possible, researchers have concluded… read more.
Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading… read more.
Eli Lilly announced results from the Phase III BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor in adult patients with chronic lymphocytic leukemia or… read more.
29th EAHP Congress highlights Approximately 10% of inpatients are labelled as ‘allergic to penicillin’ but the vast majority have not experienced a true allergic reaction. Having a penicillin… read more.
Merck known as MSD outside of the United States and Canada, announced that new clinical and outcomes research data will be presented at the American College of Cardiology’s… read more.
Pfizer Inc. announced positive topline results from the progression-free survival (PFS) analysis of the Phase III BREAKWATER study of Braftovi (encorafenib) in combination with cetuximab (Erbitux) and mFOLFOX6… read more.
When Emily Rosenfeld was doing a fellowship in maternal-fetal medicine at Rutgers Robert Wood Johnson Medical School (RWJMS), she noticed that many patients were returning to the hospital for hypertension…. read more.
Regeneron Pharmaceuticals, Inc. announced positive results from the Phase III C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically significant and… read more.
Researchers from the University of Colorado Anschutz Medical Campus studied a new method to deliver antibiotics, specifically gentamicin, directly into the bladder tissue to better treat UTIs. They did this… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Calquence…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.